Our findings establish the PCNA/PARP1 axis as a key regulator of HCC malignancy and provide theoretical support for combining PCNA inhibitors with PARP inhibitors in HCC treatment, as well as for the development of dual-target PCNA/PARP1 inhibitors. The gene discussed is PARP1; the disease is hepatocellular carcinoma.